

Recent developments in the field of adult ADHD

globally April 2024 – June 2024

Neurohaven update 8 July 2024 – A Cross

1. **New Treatment Efficacy:** A novel drug, centanafadine sustained release, has shown promising results in treating adults with ADHD. Phase 3 clinical trials have demonstrated its efficacy across various treatment histories, indicating its potential as a robust treatment option regardless of patients' prior experiences with stimulant or nonstimulant medications ([Psychiatric Times](#)).
2. **Development of US Adult ADHD Guidelines:** The American Professional Society for ADHD and Related Disorders (APSARD) is leading the development of the first-ever US guidelines for diagnosing and treating adults with ADHD. These guidelines aim to standardize care, influence policy, and enhance educational programs across the country ([Psychiatric Times](#)).
3. **Medication Shortages:** There have been ongoing shortages of stimulant medications commonly used to treat ADHD, such as lisdexamfetamine and methylphenidate. This has impacted the availability of these drugs, requiring adjustments in treatment plans for many patients ([Berkshire Healthcare Trust](#)) ([CHADD](#)).
4. **Digital Health Innovations:** Researchers at Flinders University in Australia are developing a digital health service model to assist adults with ADHD. This includes a mobile self-monitoring app designed to enhance the accessibility and effectiveness of ADHD care by involving patients more actively in their treatment plans ([Med Xpress](#)).
5. **Approval of Onyda XR:** The FDA has approved Onyda XR, a liquid nonstimulant medication for ADHD, offering a new treatment option, especially beneficial for those who may have difficulty swallowing pills ([CHADD](#)).